A great comment from SA by Mr. Karr:
This is probably the best article I've ever read about CTIX, and pretty much completely echoes my view on the company. As a shareholder since 2014, there has not been a single occurrence that has caused my confidence in the company's science to waver; on the contrary, I'm actually now a believer in Prurisol after having originally invested primarily due to Brilacidin and Kevetrin.
However, my overlying fear was that management simply could not handle the business side of running a biotech company. There have been some major credibility issues that, whether legitimate or not, have clearly damaged the company's share price, and yet, management does not seem to understand the consequences of their actions. A few things come specifically to mind: 1) the overabundance and qualityof PR's at points was met with mockery in the investment community (see: Adam Feuerstein), especially because many of them barely said anything material 2) Management has made promises that they have failed to keep--specifically, referring to an uplisting to NASDAQ, which was discussed in 2015, as well as a partnership, which has been referenced even more recently by CEO Ehrlich.
I think entering into a partnership agreement with Big Pharm would provide CTIX with a level of legitimacy that it has previously never had in the investment community. It not only would be an endorsement of their science, but it would also prevent any near-term cash concerns, vindicate the CEO, and possibly allow them to uplist. In order for this company to take the next step, I believe it is essential that they find a partner. Not that I would accept any random terms; it is OK to be patient. However, the CEO mentioned the possibility of a partnership a fairly long time ago, and longs need to feel as if they are not being misled. Leo needs to understand that the longer he holds out, the realer cash concerns and questions of legitimacy become.
This is probably the best article I've ever read about CTIX, and pretty much completely echoes my view on the company. As a shareholder since 2014, there has not been a single occurrence that has caused my confidence in the company's science to waver; on the contrary, I'm actually now a believer in Prurisol after having originally invested primarily due to Brilacidin and Kevetrin.
However, my overlying fear was that management simply could not handle the business side of running a biotech company. There have been some major credibility issues that, whether legitimate or not, have clearly damaged the company's share price, and yet, management does not seem to understand the consequences of their actions. A few things come specifically to mind: 1) the overabundance and qualityof PR's at points was met with mockery in the investment community (see: Adam Feuerstein), especially because many of them barely said anything material 2) Management has made promises that they have failed to keep--specifically, referring to an uplisting to NASDAQ, which was discussed in 2015, as well as a partnership, which has been referenced even more recently by CEO Ehrlich.
I think entering into a partnership agreement with Big Pharm would provide CTIX with a level of legitimacy that it has previously never had in the investment community. It not only would be an endorsement of their science, but it would also prevent any near-term cash concerns, vindicate the CEO, and possibly allow them to uplist. In order for this company to take the next step, I believe it is essential that they find a partner. Not that I would accept any random terms; it is OK to be patient. However, the CEO mentioned the possibility of a partnership a fairly long time ago, and longs need to feel as if they are not being misled. Leo needs to understand that the longer he holds out, the realer cash concerns and questions of legitimacy become.
2
